ICU Medical, Inc. $ICUI Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue trimmed its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 45.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,269 shares of the medical instruments supplier’s stock after selling 4,423 shares during the period. State of Alaska Department of Revenue’s holdings in ICU Medical were worth $845,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Squarepoint Ops LLC acquired a new position in ICU Medical during the 2nd quarter worth $3,744,000. Kirr Marbach & Co. LLC IN increased its stake in shares of ICU Medical by 18.4% in the 1st quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock valued at $5,702,000 after buying an additional 6,863 shares during the period. Bank of America Corp DE acquired a new stake in shares of ICU Medical in the 2nd quarter valued at $54,059,000. Legal & General Group Plc acquired a new stake in shares of ICU Medical in the 2nd quarter valued at $8,444,000. Finally, Reinhart Partners LLC. acquired a new stake in shares of ICU Medical in the 2nd quarter valued at $46,148,000. 96.10% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Elisha W. Finney sold 378 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the sale, the director directly owned 4,871 shares of the company’s stock, valued at $888,860.08. This represents a 7.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daniel Woolson sold 5,417 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $181.33, for a total value of $982,264.61. Following the completion of the sale, the vice president directly owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. This trade represents a 24.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 21,830 shares of company stock valued at $3,905,003. Insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ICUI. Weiss Ratings raised ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Zacks Research cut ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. KeyCorp lifted their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a research report on Friday, August 7th. Finally, Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Stock Performance

ICUI stock opened at $160.84 on Thursday. ICU Medical, Inc. has a twelve month low of $113.37 and a twelve month high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.02 billion, a P/E ratio of 136.31, a price-to-earnings-growth ratio of 2.03 and a beta of 0.86. The business’s fifty day moving average is $166.36 and its 200-day moving average is $150.41.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts forecast that ICU Medical, Inc. will post 7.22 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.